ICPT Jan 2024 20.000 put
| Previous close | 11.05 |
| Open | 11.05 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 20.00 |
| Expiry date | 2024-01-19 |
| Day's range | 11.05 - 11.05 |
| Contract range | N/A |
| Volume | |
| Open interest | 14 |
Simply Wall St.Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Shift From Loss To Profit
We feel now is a pretty good time to analyse Intercept Pharmaceuticals, Inc.'s ( NASDAQ:ICPT ) business as it appears...
GlobeNewswireIntercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Jefferies Healthcare Conference June 7-8, 2023
MORRISTOWN, N.J., May 31, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in investor meetings at the Jefferies Healthcare Conference at the Marriott Marquis in New York City on June 7-8, 2023. Meeting Details For investors attending the conference who wish to meet with the Intercep
ZacksBiotech Stock Roundup: IRWD Announces Buyout, ICPT, SRPT & PTCT Fall on Updates
Regulatory and pipeline updates from Intercept (ICPT) and Sarepta (SRPT) lead to a decline in the share price of both companies.
Motley FoolWhy Madrigal Pharmaceuticals Stock Is Marching Higher Today
Shares of the clinical-stage drugmaker Madrigal Pharmaceuticals (NASDAQ: MDGL) were up by 6.2% on elevated volume as of 12:16 p.m. ET Wednesday. The biotech appears to be benefiting from two key tailwinds. First, a Food and Drug Administration (FDA) panel voted overwhelmingly last Friday against approving Intercept Pharmaceuticals' (NASDAQ: ICPT) candidate, obeticholic acid, for treating pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH).
ZacksIntercept (ICPT) NASH Treatment Fails to Get GIDAC Recommendation
Intercept's (ICPT) NASH treatment does not succeed in getting GIDAC's recommendation for an approval. The committee recommends deferring approval until clinical data from another study is available.
- GlobeNewswire
Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
12 of 16 voting-eligible advisors vote “no” (with two abstentions) on question, “given the available efficacy and safety data, do the benefits of OCA 25 mg outweigh the risks in NASH patients with stage 2 or 3 fibrosis?” 15 of 16 voting-eligible advisors vote to “defer approval until clinical outcome data from trial 747-303 are submitted and reviewed, at which time the traditional approval pathway could be considered” PDUFA Target Action Date set for June 22, 2023 Company to host conference call
- GlobeNewswire
Intercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that NASDAQ has halted trading of the company’s common stock. The U.S. Food and Drug Administration’s (FDA) Gastrointestinal Drugs Advisory Committee (GIDAC) is meeting today to review obeticholic acid (OCA) as a treatment for pre-cirrhoti
ZacksIntercept (ICPT) Down Ahead of GIDAC Meeting for NASH Treatment
Intercept (ICPT) falls 14.7% a couple of days before the scheduled GIDAC meeting to review its NASH treatment on concerns of adverse events.
ZacksIntercept's (ICPT) Liver Drug Combo Gets FDA's Orphan Drug Tag
Intercept's (ICPT) fixed-dose combination of obeticholic acid and bezafibrate for the potential treatment of primary biliary cholangitis gets the FDA's Orphan Drug Designation.
- GlobeNewswire
Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)
Company on track to complete planned interim analyses from two ongoing Phase 2 studies of the OCA-bezafibrate combination in 2023 Results from planned interim analysis of Phase 2 study evaluating the effects of OCA and bezafibrate on serum biomarkers in PBC to be presented at EASL Congress 2023 MORRISTOWN, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to tre
ZacksIntercept (ICPT) Gains 26.2% YTD: What's in Store?
Intercept (ICPT) has been having a good run in the year so far, but investors are wary ahead of the upcoming advisory meeting by the FDA's Gastrointestinal Drugs Advisory Committee to review its NDA seeking approval of OCA in steatohepatitis (NASH).
- Simply Wall St.
Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Low P/S No Reason For Excitement
With a price-to-sales (or "P/S") ratio of 2.3x Intercept Pharmaceuticals, Inc. ( NASDAQ:ICPT ) may be sending very...
Motley FoolWhy Intercept Pharmaceuticals Stock Plunged Today
Shares of the non-viral liver disease specialist Intercept Pharmaceuticals (NASDAQ: ICPT) are under heavy pressure today. The big loss came in response to weaker-than-expected 2023 first-quarter sales of Intercept's primary biliary cholangitis (PBC) therapy, Ocaliva (obeticholic acid). This relatively modest revenue miss probably isn't the reason Intercept's shares are falling today.
ZacksIntercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates
Intercept (ICPT) delivered earnings and revenue surprises of -35.09% and 7.24%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH
Ocaliva® net sales of $68.0 million, representing 15% growth over the prior year quarter Gastrointestinal Drugs Advisory Committee (GIDAC) Meeting set for May 19, 2023, to review obeticholic acid (OCA) as a treatment for pre-cirrhotic fibrosis due to NASH; PDUFA Target Action Date set for June 22, 2023 Company updates progress of OCA-bezafibrate fixed-dose combination development program in PBC, including acceptance of new Phase 2 data at EASL Congress 2023 Company to host conference call today
- GlobeNewswire
Intercept Announces New Data to be Presented at The European Association for the Study of the Liver (EASL) Congress 2023 and Provides Update on OCA-bezafibrate Fixed-Dose Combination (FDC) Development Program
Seven abstracts in primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) accepted at EASL 2023 Accepted abstracts include podium presentation of new data from the planned interim analysis of a Phase 2 study of investigational combination of obeticholic acid (OCA) and bezafibrate in PBC Company expects to complete planned interim analyses from two ongoing Phase 2 studies of OCA-bezafibrate in 2023 in preparation for end-of-phase 2 meeting with the U.S. Food and Drug Administra
ZacksIntercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksStrength Seen in Celldex (CLDX): Can Its 7.1% Jump Turn into More Strength?
Celldex (CLDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- GlobeNewswire
Intercept to Announce First Quarter 2023 Financial Results and Provide Update on Commercial Launch Strategy for NASH on April 27, 2023
MORRISTOWN, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2023 financial results on Thursday, April 27, 2023, and provide an update on the commercial launch strategy for obeticholic acid (OCA) in nonalcoholic steatohepatitis (NASH). The announcement will be followed by a confere
ZacksIntercept (ICPT) Moves 15.0% Higher: Will This Strength Last?
Intercept (ICPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
ZacksIntercept (ICPT) Stock Down on FDA Committee Update on NDA
Intercept (ICPT) declines on news of a GIDAC meeting to discuss the NDA for the OCA for NASH in May.
- Simply Wall St.
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) down to US$672m market cap, but institutional owners may not be as affected after a year of 8.0% returns
Key Insights Institutions' substantial holdings in Intercept Pharmaceuticals implies that they have significant...
- Zacks
Heres Why Intercept (ICPT) Stock is Up 28.7% in 3 Months
Intercept (ICPT) gains 28.7% in the past 3 months on NDA's acceptance for NASH treatment and Ocaliva's performance.
- GlobeNewswire
Intercept Announces FDA Advisory Committee Meeting Date for Obeticholic Acid as a Treatment for Pre-Cirrhotic Liver Fibrosis due to NASH
Advisory Committee Meeting scheduled for May 19, 2023 PDUFA Target Action Date is June 22, 2023 MORRISTOWN, N.J., March 10, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug Administration (FDA) will discuss Intercept’s new drug a
- GlobeNewswire
Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Barclays Global Healthcare Conference March 14, 2023
MORRISTOWN, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in investor meetings at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel on March 14, 2023. Meeting Details For investors attending the conference who wish to meet with the Intercept